APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmacokinetic Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmacokinetic Testing Market Outlook and Growth Opportunities 2026

12 August 2026191 pages

Choose your research edition.

Industry ResearchPharmacokinetic Testing Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacokinetic Testing Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Pharmacokinetic Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacokinetic Testing Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacokinetic Testing Market Analysis and Forecast 2026-2032170 pages · $4,950 USD

Market perspective

The global Pharmacokinetic Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pharmacokinetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharmacokinetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharmacokinetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pharmacokinetic Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pharmacokinetic Testing market include Certara, L.P., Evotec AG, Pacific BioLabs, GVK Biosciences Private Limited, SGS SA, LGC Limited, Pharmaceutical Product Development, LLC, Charles River Laboratories International, Inc. and Creative Bioarray, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pharmacokinetic Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmacokinetic Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmacokinetic Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmacokinetic Testing market.

Pharmacokinetic Testing Segment by Company

Certara, L.P.

Evotec AG

Pacific BioLabs

GVK Biosciences Private Limited

SGS SA

LGC Limited

Pharmaceutical Product Development, LLC

Charles River Laboratories International, Inc.

Creative Bioarray

Pharmacokinetic Testing Segment by Type

Oral Dissolution Testing (FDC)

Intravenous Titration Test (IVRT)

Cell Line In-house Testing (ICR)

Pharmacokinetic Testing Segment by Application

Hospital

Clinic

Research Institutions

Pharmacokinetic Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmacokinetic Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharmacokinetic Testing key companies, revenue, market share, and recent developments.

3. To split the Pharmacokinetic Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharmacokinetic Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmacokinetic Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmacokinetic Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacokinetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacokinetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacokinetic Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmacokinetic Testing industry.

Chapter 3: Detailed analysis of Pharmacokinetic Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharmacokinetic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharmacokinetic Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmacokinetic Testing Industry Trends Table 2. Pharmacokinetic Testing Industry Drivers Table 3. Pharmacokinetic Testing Industry Opportunities and Challenges Table 4. Pharmacokinetic Testing Industry Restraints Table 5. Global Pharmacokinetic Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmacokinetic Testing Revenue Share by Company (2021-2026) Table 7. Global Pharmacokinetic Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharmacokinetic Testing Key Company Manufacturing Base & Headquarters Table 9. Global Pharmacokinetic Testing Company, Product Type & Application Table 10. Global Pharmacokinetic Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharmacokinetic Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Dissolution Testing (FDC) Table 15. Significant Companies of Intravenous Titration Test (IVRT) Table 16. Significant Companies of Cell Line In-house Testing (ICR) Table 17. Global Pharmacokinetic Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Pharmacokinetic Testing Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Pharmacokinetic Testing Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Pharmacokinetic Testing Sales Value Share by Type (2021-2026) Table 21. Global Pharmacokinetic Testing Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Significant Companies of Research Institutions Table 25. Global Pharmacokinetic Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pharmacokinetic Testing Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Pharmacokinetic Testing Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Pharmacokinetic Testing Sales Value Share by Application (2021-2026) Table 29. Global Pharmacokinetic Testing Sales Value Share by Application (2027-2032) Table 30. Global Pharmacokinetic Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Pharmacokinetic Testing Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Pharmacokinetic Testing Sales Value Share by Region (2021-2026) Table 33. Global Pharmacokinetic Testing Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Pharmacokinetic Testing Sales Value Share by Region (2027-2032) Table 35. Global Pharmacokinetic Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Pharmacokinetic Testing Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Pharmacokinetic Testing Sales Value Market Share by Country (2021-2026) Table 38. Global Pharmacokinetic Testing Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Pharmacokinetic Testing Sales Value Market Share by Country (2027-2032) Table 40. Certara, L.P. Company Information Table 41. Certara, L.P. Business Overview Table 42. Certara, L.P. Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Certara, L.P. Pharmacokinetic Testing Product Portfolio Table 44. Certara, L.P. Recent Development Table 45. Evotec AG Company Information Table 46. Evotec AG Business Overview Table 47. Evotec AG Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Evotec AG Pharmacokinetic Testing Product Portfolio Table 49. Evotec AG Recent Development Table 50. Pacific BioLabs Company Information Table 51. Pacific BioLabs Business Overview Table 52. Pacific BioLabs Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Pacific BioLabs Pharmacokinetic Testing Product Portfolio Table 54. Pacific BioLabs Recent Development Table 55. GVK Biosciences Private Limited Company Information Table 56. GVK Biosciences Private Limited Business Overview Table 57. GVK Biosciences Private Limited Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. GVK Biosciences Private Limited Pharmacokinetic Testing Product Portfolio Table 59. GVK Biosciences Private Limited Recent Development Table 60. SGS SA Company Information Table 61. SGS SA Business Overview Table 62. SGS SA Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. SGS SA Pharmacokinetic Testing Product Portfolio Table 64. SGS SA Recent Development Table 65. LGC Limited Company Information Table 66. LGC Limited Business Overview Table 67. LGC Limited Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. LGC Limited Pharmacokinetic Testing Product Portfolio Table 69. LGC Limited Recent Development Table 70. Pharmaceutical Product Development, LLC Company Information Table 71. Pharmaceutical Product Development, LLC Business Overview Table 72. Pharmaceutical Product Development, LLC Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pharmaceutical Product Development, LLC Pharmacokinetic Testing Product Portfolio Table 74. Pharmaceutical Product Development, LLC Recent Development Table 75. Charles River Laboratories International, Inc. Company Information Table 76. Charles River Laboratories International, Inc. Business Overview Table 77. Charles River Laboratories International, Inc. Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Charles River Laboratories International, Inc. Pharmacokinetic Testing Product Portfolio Table 79. Charles River Laboratories International, Inc. Recent Development Table 80. Creative Bioarray Company Information Table 81. Creative Bioarray Business Overview Table 82. Creative Bioarray Pharmacokinetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Creative Bioarray Pharmacokinetic Testing Product Portfolio Table 84. Creative Bioarray Recent Development Table 85. Research Programs/Design for This Report Table 86. Authors List of This Report Table 87. Secondary Sources Table 88. Primary Sources List of Figures Figure 1. Pharmacokinetic Testing Product Image Figure 2. Global Pharmacokinetic Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmacokinetic Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharmacokinetic Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Dissolution Testing (FDC) Image Figure 8. Intravenous Titration Test (IVRT) Image Figure 9. Cell Line In-house Testing (ICR) Image Figure 10. Global Pharmacokinetic Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Pharmacokinetic Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Pharmacokinetic Testing Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Research Institutions Image Figure 16. Global Pharmacokinetic Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Pharmacokinetic Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Pharmacokinetic Testing Sales Value Share by Application (2021-2032) Figure 19. Global Pharmacokinetic Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Pharmacokinetic Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Pharmacokinetic Testing Sales Value (2021-2032) & (US$ Million) Figure 22. North America Pharmacokinetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Pharmacokinetic Testing Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Pharmacokinetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Pharmacokinetic Testing Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Pharmacokinetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Pharmacokinetic Testing Sales Value (2021-2032) & (US$ Million) Figure 28. South America Pharmacokinetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Pharmacokinetic Testing Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Pharmacokinetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Pharmacokinetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Dissolution Testing (FDC)
  • Intravenous Titration Test (IVRT)
  • Cell Line In-house Testing (ICR)
Applications
  • Hospital
  • Clinic
  • Research Institutions
Companies covered
  • Certara, L.P.
  • Evotec AG
  • Pacific BioLabs
  • GVK Biosciences Private Limited
  • SGS SA
  • LGC Limited
  • Pharmaceutical Product Development, LLC
  • Charles River Laboratories International, Inc.
  • Creative Bioarray

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharmacokinetic Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharmacokinetic Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharmacokinetic Testing Market Dynamics
  1. 2.1 Pharmacokinetic Testing Industry Trends
  2. 2.2 Pharmacokinetic Testing Industry Drivers
  3. 2.3 Pharmacokinetic Testing Industry Opportunities and Challenges
  4. 2.4 Pharmacokinetic Testing Industry Restraints
3 Pharmacokinetic Testing Market by Company
  1. 3.1 Global Pharmacokinetic Testing Company Revenue Ranking in 2025
  2. 3.2 Global Pharmacokinetic Testing Revenue by Company (2021-2026)
  3. 3.3 Global Pharmacokinetic Testing Company Ranking (2024-2026)
  4. 3.4 Global Pharmacokinetic Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharmacokinetic Testing Company Product Type and Application
  6. 3.6 Global Pharmacokinetic Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharmacokinetic Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharmacokinetic Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharmacokinetic Testing Market by Type
  1. 4.1 Pharmacokinetic Testing Type Introduction
  2. 4.1.1 Oral Dissolution Testing (FDC)
  3. 4.1.2 Intravenous Titration Test (IVRT)
  4. 4.1.3 Cell Line In-house Testing (ICR)
  5. 4.2 Global Pharmacokinetic Testing Sales Value by Type
  6. 4.2.1 Global Pharmacokinetic Testing Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pharmacokinetic Testing Sales Value by Type (2021-2032)
  8. 4.2.3 Global Pharmacokinetic Testing Sales Value Share by Type (2021-2032)
5 Pharmacokinetic Testing Market by Application
  1. 5.1 Pharmacokinetic Testing Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Research Institutions
  5. 5.2 Global Pharmacokinetic Testing Sales Value by Application
  6. 5.2.1 Global Pharmacokinetic Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pharmacokinetic Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global Pharmacokinetic Testing Sales Value Share by Application (2021-2032)
6 Pharmacokinetic Testing Regional Value Analysis
  1. 6.1 Global Pharmacokinetic Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmacokinetic Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharmacokinetic Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharmacokinetic Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharmacokinetic Testing Sales Value (2021-2032)
  7. 6.3.2 North America Pharmacokinetic Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharmacokinetic Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Pharmacokinetic Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharmacokinetic Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharmacokinetic Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharmacokinetic Testing Sales Value (2021-2032)
  16. 6.6.2 South America Pharmacokinetic Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharmacokinetic Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharmacokinetic Testing Sales Value Share by Country, 2025 VS 2032
7 Pharmacokinetic Testing Country-level Value Analysis
  1. 7.1 Global Pharmacokinetic Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmacokinetic Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharmacokinetic Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharmacokinetic Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharmacokinetic Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharmacokinetic Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharmacokinetic Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Certara, L.P.
  2. 8.1.1 Certara, L.P. Company Information
  3. 8.1.2 Certara, L.P. Business Overview
  4. 8.1.3 Certara, L.P. Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Certara, L.P. Pharmacokinetic Testing Product Portfolio
  6. 8.1.5 Certara, L.P. Recent Developments
  7. 8.2 Evotec AG
  8. 8.2.1 Evotec AG Company Information
  9. 8.2.2 Evotec AG Business Overview
  10. 8.2.3 Evotec AG Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Evotec AG Pharmacokinetic Testing Product Portfolio
  12. 8.2.5 Evotec AG Recent Developments
  13. 8.3 Pacific BioLabs
  14. 8.3.1 Pacific BioLabs Company Information
  15. 8.3.2 Pacific BioLabs Business Overview
  16. 8.3.3 Pacific BioLabs Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pacific BioLabs Pharmacokinetic Testing Product Portfolio
  18. 8.3.5 Pacific BioLabs Recent Developments
  19. 8.4 GVK Biosciences Private Limited
  20. 8.4.1 GVK Biosciences Private Limited Company Information
  21. 8.4.2 GVK Biosciences Private Limited Business Overview
  22. 8.4.3 GVK Biosciences Private Limited Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GVK Biosciences Private Limited Pharmacokinetic Testing Product Portfolio
  24. 8.4.5 GVK Biosciences Private Limited Recent Developments
  25. 8.5 SGS SA
  26. 8.5.1 SGS SA Company Information
  27. 8.5.2 SGS SA Business Overview
  28. 8.5.3 SGS SA Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SGS SA Pharmacokinetic Testing Product Portfolio
  30. 8.5.5 SGS SA Recent Developments
  31. 8.6 LGC Limited
  32. 8.6.1 LGC Limited Company Information
  33. 8.6.2 LGC Limited Business Overview
  34. 8.6.3 LGC Limited Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LGC Limited Pharmacokinetic Testing Product Portfolio
  36. 8.6.5 LGC Limited Recent Developments
  37. 8.7 Pharmaceutical Product Development, LLC
  38. 8.7.1 Pharmaceutical Product Development, LLC Company Information
  39. 8.7.2 Pharmaceutical Product Development, LLC Business Overview
  40. 8.7.3 Pharmaceutical Product Development, LLC Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pharmaceutical Product Development, LLC Pharmacokinetic Testing Product Portfolio
  42. 8.7.5 Pharmaceutical Product Development, LLC Recent Developments
  43. 8.8 Charles River Laboratories International, Inc.
  44. 8.8.1 Charles River Laboratories International, Inc. Company Information
  45. 8.8.2 Charles River Laboratories International, Inc. Business Overview
  46. 8.8.3 Charles River Laboratories International, Inc. Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Charles River Laboratories International, Inc. Pharmacokinetic Testing Product Portfolio
  48. 8.8.5 Charles River Laboratories International, Inc. Recent Developments
  49. 8.9 Creative Bioarray
  50. 8.9.1 Creative Bioarray Company Information
  51. 8.9.2 Creative Bioarray Business Overview
  52. 8.9.3 Creative Bioarray Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Creative Bioarray Pharmacokinetic Testing Product Portfolio
  54. 8.9.5 Creative Bioarray Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst